AbbVie Inc. Non-current Liabilities (Other)

Non-current Liabilities (Other) of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Non-current Liabilities (Other) growth rates and interactive chart.


Highlights and Quick Summary

  • Non-current Liabilities (Other) for the quarter ending December 30, 2020 was $27.6 Billion (a 18.06% increase compared to previous quarter)
  • Year-over-year quarterly Non-current Liabilities (Other) increased by 54.23%
  • Annual Non-current Liabilities (Other) for 2020 was $27.6 Billion (a 56.88% increase from previous year)
  • Annual Non-current Liabilities (Other) for 2019 was $17.6 Billion (a 21.44% increase from previous year)
  • Annual Non-current Liabilities (Other) for 2018 was $14.5 Billion (a -7.15% decrease from previous year)
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Non-current Liabilities (Other) of AbbVie Inc.

Most recent Non-current Liabilities (Other)of ABBV including historical data for past 10 years.

Interactive Chart of Non-current Liabilities (Other) of AbbVie Inc.

AbbVie Inc. Non-current Liabilities (Other) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $27,607.0 $23,384.0 $23,306.0 $17,900.0 $27,607.0
2019 $17,597.0 $15,990.0 $16,000.0 $14,509.0 $17,597.0
2018 $14,490.0 $15,721.0 $15,543.0 $15,521.0 $14,490.0
2017 $15,605.0 $8,999.0 $8,518.0 $8,499.0 $15,605.0
2016 $8,352.0 $7,646.0 $7,791.0 $3,513.0 $8,352.0
2015 $3,695.0 $3,801.0 $3,918.0 $3,589.0 $3,695.0
2014 $3,681.0 $2,705.0 $3,040.0 $3,358.0 $3,681.0
2013 $3,535.0 $3,425.0 $3,221.0 $2,845.0 $3,535.0
2012 $2,239.0 $1,693.25 $1,364.76 $1,395.84 $2,239.0
2011 $1,660.0 $1,660.0
2010 $1,670.45 $1,670.46

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.